Nathan Gabayan*, Ali Muhammad, Afshin Eli Gabayan
Our providers’ continuous efforts to obtain Next-generation sequencing for their cancer patients as early as possible followed by matched therapy has provided new therapeutic options to our solid tumors patients. We report our experience here with this approach in everyday clinical practice at the Beverly Hills Cancer Center along with our robust clinical research program. This retrospective study included 95 solid tumor patients who were genotyped with the FDA-approved Guardant360 CDx that provides comprehensive genomic results from a blood draw in seven days X. Our oncologists use it on regular basis for tumor mutation profiling, also known as Comprehensive Genomic Profiling (CGP), across all solid cancers and also as a companion diagnostic to identify non-small cell lung cancer patients who may benefit from treatment with Tagrisso® (osimertinib), RYBREVANT™ (amivantamab-vmjw), and LUMAKRAS™ (sotorasib).